InvestorsHub Logo
Followers 5
Posts 1278
Boards Moderated 0
Alias Born 04/15/2019

Re: None

Wednesday, 09/27/2023 11:57:57 PM

Wednesday, September 27, 2023 11:57:57 PM

Post# of 2829
Conclusions:

Preliminary results from this pilot study of MCGN in mPDAC were promising, with a durable PR rate of 55% and disease control rate (DCR) of 82%, compared to historic PRs and DCRs of 23% and 48% reported with gemcitabine and nab-paclitaxel (GN), respectively. Based on these results, the study was amended to transition to a randomized phase 2 trial testing MCGN compared to GN (N=112). The primary endpoint is progression free survival (PFS).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLRX News